The age-dependent association of risk factors with pancreatic cancer.

Genome-Wide Association Study Humans Male Pancreatic Neoplasms / etiology Prospective Studies Risk Factors Pancreatic Neoplasms
age lifestyle modification pancreatic cancer polygenic risk score risk factor

Journal

Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735

Informations de publication

Date de publication:
07 2022
Historique:
received: 07 12 2021
revised: 04 03 2022
accepted: 31 03 2022
pubmed: 11 4 2022
medline: 22 6 2022
entrez: 10 4 2022
Statut: ppublish

Résumé

Pancreatic cancer presents as advanced disease in >80% of patients; yet, appropriate ages to consider prevention and early detection strategies are poorly defined. We investigated age-specific associations and attributable risks of pancreatic cancer for established modifiable and non-modifiable risk factors. We included 167 483 participants from two prospective US cohort studies with 1190 incident cases of pancreatic cancer during >30 years of follow-up; 5107 pancreatic cancer cases and 8845 control participants of European ancestry from a completed multicenter genome-wide association study (GWAS); and 248 893 pancreatic cancer cases documented in the US Surveillance, Epidemiology, and End Results (SEER) Program. Across different age categories, we investigated cigarette smoking, obesity, diabetes, height, and non-O blood group in the prospective cohorts; weighted polygenic risk score of 22 previously identified single nucleotide polymorphisms in the GWAS; and male sex and black race in the SEER Program. In the prospective cohorts, all five risk factors were more strongly associated with pancreatic cancer risk among younger participants, with associations attenuated among those aged >70 years. The hazard ratios comparing participants with three to five risk factors with those with no risk factors were 9.24 [95% confidence interval (CI) 4.11-20.77] among those aged ≤60 years, 3.00 (95% CI 1.85-4.86) among those aged 61-70 years, and 1.46 (95% CI 1.10-1.94) among those aged >70 years (P Established risk factors are more strongly associated with earlier-onset pancreatic cancer, emphasizing the importance of age at initiation for cancer prevention and control programs targeting this highly lethal malignancy.

Sections du résumé

BACKGROUND
Pancreatic cancer presents as advanced disease in >80% of patients; yet, appropriate ages to consider prevention and early detection strategies are poorly defined. We investigated age-specific associations and attributable risks of pancreatic cancer for established modifiable and non-modifiable risk factors.
PATIENTS AND METHODS
We included 167 483 participants from two prospective US cohort studies with 1190 incident cases of pancreatic cancer during >30 years of follow-up; 5107 pancreatic cancer cases and 8845 control participants of European ancestry from a completed multicenter genome-wide association study (GWAS); and 248 893 pancreatic cancer cases documented in the US Surveillance, Epidemiology, and End Results (SEER) Program. Across different age categories, we investigated cigarette smoking, obesity, diabetes, height, and non-O blood group in the prospective cohorts; weighted polygenic risk score of 22 previously identified single nucleotide polymorphisms in the GWAS; and male sex and black race in the SEER Program.
RESULTS
In the prospective cohorts, all five risk factors were more strongly associated with pancreatic cancer risk among younger participants, with associations attenuated among those aged >70 years. The hazard ratios comparing participants with three to five risk factors with those with no risk factors were 9.24 [95% confidence interval (CI) 4.11-20.77] among those aged ≤60 years, 3.00 (95% CI 1.85-4.86) among those aged 61-70 years, and 1.46 (95% CI 1.10-1.94) among those aged >70 years (P
CONCLUSIONS
Established risk factors are more strongly associated with earlier-onset pancreatic cancer, emphasizing the importance of age at initiation for cancer prevention and control programs targeting this highly lethal malignancy.

Identifiants

DOI: 10.1016/j.annonc.2022.03.276 PMID: 35398288 PMC: PMC9233063
pubmed: 35398288
pii: S0923-7534(22)00672-X
doi: 10.1016/j.annonc.2022.03.276
pmc: PMC9233063
mid: NIHMS1796471
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

693-701

Subventions

Organisme : NCI NIH HHS
ID : P01 CA087969
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA062924
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA222159
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186107
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA127003
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA247283
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA210171
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA182883
Pays : United States

Investigateurs

L T Amundadottir (LT)
E Ardanaz (E)
A A Arslan (AA)
L E Beane-Freeman (LE)
P M Bracci (PM)
B Bueno-de-Mesquita (B)
M Du (M)
S Gallinger (S)
G G Giles (GG)
P J Goodman (PJ)
V A Katzke (VA)
A P Klein (AP)
C Kooperberg (C)
P Kraft (P)
D Li (D)
N Malats (N)
L L Marchand (LL)
M L McCullough (ML)
R L Milne (RL)
J P Neoptolemos (JP)
S Perdomo (S)
G M Petersen (GM)
H A Risch (HA)
X O Shu (XO)
R Z Stolzenberg-Solomon (RZ)
S K Van Den Eeden (SK)
K Visvanathan (K)
E White (E)
B M Wolpin (BM)
W Zheng (W)

Informations de copyright

Copyright © 2022 European Society for Medical Oncology. All rights reserved.

Références

Obesity (Silver Spring). 2019 Oct;27(10):1711-1719
pubmed: 31544344
Cancer Causes Control. 2007 Jun;18(5):571-9
pubmed: 17387622
Lancet. 1991 Aug 24;338(8765):464-8
pubmed: 1678444
Ann Oncol. 2020 Jun;31(6):745-759
pubmed: 33506766
Int J Epidemiol. 2018 Apr 1;47(2):427-439
pubmed: 29149259
JAMA. 2018 Jun 19;319(23):2401-2409
pubmed: 29922827
JAMA. 2001 Aug 22-29;286(8):921-9
pubmed: 11509056
Arch Intern Med. 1996 Oct 28;156(19):2255-60
pubmed: 8885826
Gastroenterology. 2008 Jan;134(1):95-101
pubmed: 18061176
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
J Natl Cancer Inst. 2008 Dec 17;100(24):1755-62
pubmed: 19066267
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Natl Cancer Inst. 2013 Sep 4;105(17):1298-305
pubmed: 23949329
J Natl Cancer Inst. 2009 Mar 18;101(6):424-31
pubmed: 19276450
Science. 2015 Jan 2;347(6217):78-81
pubmed: 25554788
Nat Genet. 2014 Sep;46(9):994-1000
pubmed: 25086665
Gastroenterology. 2019 May;156(6):1560-1563
pubmed: 30926350
Cancer. 2004 Dec 15;101(12):2722-6
pubmed: 15534880
Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1894-7
pubmed: 17855711
Oncotarget. 2016 Oct 11;7(41):66328-66343
pubmed: 27579533
Clin Gastroenterol Hepatol. 2020 Jan;18(1):171-178.e10
pubmed: 31202981
Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10202-10207
pubmed: 28874546
Clin Gastroenterol Hepatol. 2006 Sep;4(9):1143-7
pubmed: 16861052
Nat Commun. 2018 Feb 8;9(1):556
pubmed: 29422604
Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):429-37
pubmed: 11352851
Nat Genet. 2010 Mar;42(3):224-8
pubmed: 20101243
Int J Biol Sci. 2016 Jan 28;12(3):314-25
pubmed: 26929738
Nat Genet. 2015 Aug;47(8):911-6
pubmed: 26098869
Nat Genet. 2009 Sep;41(9):986-90
pubmed: 19648918
Am J Epidemiol. 1994 Dec 1;140(11):1016-9
pubmed: 7985649
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
JAMA Oncol. 2020 Oct 1;6(10):e202948
pubmed: 32789511
JAMA. 2021 Nov 23;326(20):2075-2077
pubmed: 34689206
JAMA. 2009 Jun 24;301(24):2553-62
pubmed: 19549972
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Science. 2017 Mar 24;355(6331):1330-1334
pubmed: 28336671
J Womens Health. 1997 Feb;6(1):49-62
pubmed: 9065374
Pancreas. 2021 Mar 1;50(3):251-279
pubmed: 33835956
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):999-1008
pubmed: 32321713

Auteurs

C Yuan (C)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA. Electronic address: chen_yuan@dfci.harvard.edu.

J Kim (J)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA.

Q L Wang (QL)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA.

A A Lee (AA)

Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.

A Babic (A)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA.

L T Amundadottir (LT)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA.

A P Klein (AP)

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, USA; Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins School of Medicine, Baltimore, USA.

D Li (D)

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

M L McCullough (ML)

Department of Population Science, American Cancer Society, Atlanta, USA.

G M Petersen (GM)

Department of Quantitative Health Sciences, Mayo Clinic College of Medicine, Rochester, USA.

H A Risch (HA)

Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, USA.

R Z Stolzenberg-Solomon (RZ)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA.

K Perez (K)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA.

K Ng (K)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA.

E L Giovannucci (EL)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.

M J Stampfer (MJ)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.

P Kraft (P)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA.

B M Wolpin (BM)

Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Épidémiologie moléculaire › Étude d'association pangénomique › The age-dependent association of risk factors...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The age-dependent association of risk factors...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › The age-dependent association of risk factors...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › The age-dependent association of risk factors...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › The age-dependent association of risk factors...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › The age-dependent association of risk factors...